Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor

Scott B. Saxman, Craig R. Nichols, Lawrence Einhorn

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Study objectives: The purpose of this study is to determine whether co- administration of granulocyte colony stimulating factor (G-CSF) and bleomycin results in enhanced pulmonary toxicity compared with bleomycin alone. Design: A retrospective analysis comparing two groups of patients with advanced germ cell tumors receiving combination chemotherapy that includes bleomycin with or without G-CSF. Setting: Indiana University Medical Center. Patients: Group A consisted of 29 patients with advanced-stage germ cell tumors who were treated with combination chemotherapy that included bleomycin. All patients received concurrent prophylactic G-CSF. Group B consisted of 57 patients with advanced-stage germ cell tumors who were treated on a phase 3 study comparing standard BEP (bleomycin, etoposide, cisplatin) to BEP with twice the cisplatin dose. None of these patients received growth factor. Results: Of the 29 patients who received concurrent chemotherapy and G-CSF, ten (34%; 95% confidence interval [CI], 17.9 to 54.3%) were believed to have clinically significant bleomycin toxicity. Of the 57 patients who did not receive growth factor, 19 (33%; 95% CI, 21.4 to 47.1%) had bleomycin-related toxicity. There was no difference in the incidence of pulmonary toxicity between the groups (p = 1.00 by Fisher's Exact Test). Conclusions: There is no increase in pulmonary toxicity with co-administration of G-CSF and bleomycin compared to bleomycin alone in patients with advanced germ cell tumors.

Original languageEnglish
Pages (from-to)657-660
Number of pages4
JournalChest
Volume111
Issue number3
StatePublished - 1997

Fingerprint

Germ Cell and Embryonal Neoplasms
Bleomycin
Granulocyte Colony-Stimulating Factor
Lung
Cisplatin
Etoposide
Combination Drug Therapy
Intercellular Signaling Peptides and Proteins
Confidence Intervals
Drug Therapy
Incidence

Keywords

  • bleomycin
  • germ cell tumors
  • granulocyte colony stimulating factor
  • pulmonary toxicity

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. / Saxman, Scott B.; Nichols, Craig R.; Einhorn, Lawrence.

In: Chest, Vol. 111, No. 3, 1997, p. 657-660.

Research output: Contribution to journalArticle

@article{eb4c8bfb4bad40baada28f0b216cc627,
title = "Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor",
abstract = "Study objectives: The purpose of this study is to determine whether co- administration of granulocyte colony stimulating factor (G-CSF) and bleomycin results in enhanced pulmonary toxicity compared with bleomycin alone. Design: A retrospective analysis comparing two groups of patients with advanced germ cell tumors receiving combination chemotherapy that includes bleomycin with or without G-CSF. Setting: Indiana University Medical Center. Patients: Group A consisted of 29 patients with advanced-stage germ cell tumors who were treated with combination chemotherapy that included bleomycin. All patients received concurrent prophylactic G-CSF. Group B consisted of 57 patients with advanced-stage germ cell tumors who were treated on a phase 3 study comparing standard BEP (bleomycin, etoposide, cisplatin) to BEP with twice the cisplatin dose. None of these patients received growth factor. Results: Of the 29 patients who received concurrent chemotherapy and G-CSF, ten (34{\%}; 95{\%} confidence interval [CI], 17.9 to 54.3{\%}) were believed to have clinically significant bleomycin toxicity. Of the 57 patients who did not receive growth factor, 19 (33{\%}; 95{\%} CI, 21.4 to 47.1{\%}) had bleomycin-related toxicity. There was no difference in the incidence of pulmonary toxicity between the groups (p = 1.00 by Fisher's Exact Test). Conclusions: There is no increase in pulmonary toxicity with co-administration of G-CSF and bleomycin compared to bleomycin alone in patients with advanced germ cell tumors.",
keywords = "bleomycin, germ cell tumors, granulocyte colony stimulating factor, pulmonary toxicity",
author = "Saxman, {Scott B.} and Nichols, {Craig R.} and Lawrence Einhorn",
year = "1997",
language = "English",
volume = "111",
pages = "657--660",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor

AU - Saxman, Scott B.

AU - Nichols, Craig R.

AU - Einhorn, Lawrence

PY - 1997

Y1 - 1997

N2 - Study objectives: The purpose of this study is to determine whether co- administration of granulocyte colony stimulating factor (G-CSF) and bleomycin results in enhanced pulmonary toxicity compared with bleomycin alone. Design: A retrospective analysis comparing two groups of patients with advanced germ cell tumors receiving combination chemotherapy that includes bleomycin with or without G-CSF. Setting: Indiana University Medical Center. Patients: Group A consisted of 29 patients with advanced-stage germ cell tumors who were treated with combination chemotherapy that included bleomycin. All patients received concurrent prophylactic G-CSF. Group B consisted of 57 patients with advanced-stage germ cell tumors who were treated on a phase 3 study comparing standard BEP (bleomycin, etoposide, cisplatin) to BEP with twice the cisplatin dose. None of these patients received growth factor. Results: Of the 29 patients who received concurrent chemotherapy and G-CSF, ten (34%; 95% confidence interval [CI], 17.9 to 54.3%) were believed to have clinically significant bleomycin toxicity. Of the 57 patients who did not receive growth factor, 19 (33%; 95% CI, 21.4 to 47.1%) had bleomycin-related toxicity. There was no difference in the incidence of pulmonary toxicity between the groups (p = 1.00 by Fisher's Exact Test). Conclusions: There is no increase in pulmonary toxicity with co-administration of G-CSF and bleomycin compared to bleomycin alone in patients with advanced germ cell tumors.

AB - Study objectives: The purpose of this study is to determine whether co- administration of granulocyte colony stimulating factor (G-CSF) and bleomycin results in enhanced pulmonary toxicity compared with bleomycin alone. Design: A retrospective analysis comparing two groups of patients with advanced germ cell tumors receiving combination chemotherapy that includes bleomycin with or without G-CSF. Setting: Indiana University Medical Center. Patients: Group A consisted of 29 patients with advanced-stage germ cell tumors who were treated with combination chemotherapy that included bleomycin. All patients received concurrent prophylactic G-CSF. Group B consisted of 57 patients with advanced-stage germ cell tumors who were treated on a phase 3 study comparing standard BEP (bleomycin, etoposide, cisplatin) to BEP with twice the cisplatin dose. None of these patients received growth factor. Results: Of the 29 patients who received concurrent chemotherapy and G-CSF, ten (34%; 95% confidence interval [CI], 17.9 to 54.3%) were believed to have clinically significant bleomycin toxicity. Of the 57 patients who did not receive growth factor, 19 (33%; 95% CI, 21.4 to 47.1%) had bleomycin-related toxicity. There was no difference in the incidence of pulmonary toxicity between the groups (p = 1.00 by Fisher's Exact Test). Conclusions: There is no increase in pulmonary toxicity with co-administration of G-CSF and bleomycin compared to bleomycin alone in patients with advanced germ cell tumors.

KW - bleomycin

KW - germ cell tumors

KW - granulocyte colony stimulating factor

KW - pulmonary toxicity

UR - http://www.scopus.com/inward/record.url?scp=0030952276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030952276&partnerID=8YFLogxK

M3 - Article

C2 - 9118704

AN - SCOPUS:0030952276

VL - 111

SP - 657

EP - 660

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -